Search - tctmd.com

Displaying 41 - 60 of 157

Sort: Relevancy | Date

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Thomas Pilgrim

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Tullio Palmerini

October 30, 2016

News Industry News

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

October 30, 2016

News Industry News

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

October 30, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Michael O'Riordan

June 06, 2016

News Industry News

Medinol Announces Outstanding Results in a Randomized Trial of a New Drug Eluting Stent

May 17, 2016

News Daily News

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Michael O'Riordan

March 30, 2016

News Daily News

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

Michael O'Riordan

March 16, 2016

News Daily News

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Michael O'Riordan

March 14, 2016

News Industry News

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

February 24, 2016

News Industry News

Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial Against Xience

December 08, 2015

Presentation TCT 2015

TCT 48: Early Vascular Responses to Everolimus-Eluting Cobalt-Chromium Stent for the Treatment of Stable Coronary Artery Disease The Results of MECHANISM Elective 1-Month OCT Follow-up Cohort

Presenter: Stephan Achenbach, Marc D. Feldman, Toshiro Shinke

October 13, 2015

Presentation TCT 2015

A New Durable-PolymerBased Cobalt Chromium Stent: Rationale for and Design Characteristics of the BioNIR Stent and Clinical Development Program

Presenter: Fernando Alfonso, Juan F. Granada, Pieter C. Smits

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Daily News

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Yael L. Maxwell

October 02, 2015

Advertisement

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Stent Design and Comprehensive Data Review: Orsiro Cobalt Chromium Sirolimus-Eluting Stents

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Medinol Announces Outstanding Results in a Randomized Trial of a New Drug Eluting Stent

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial Against Xience

TCT 48: Early Vascular Responses to Everolimus-Eluting Cobalt-Chromium Stent for the Treatment of Stable Coronary Artery Disease The Results of MECHANISM Elective 1-Month OCT Follow-up Cohort

A New Durable-PolymerBased Cobalt Chromium Stent: Rationale for and Design Characteristics of the BioNIR Stent and Clinical Development Program

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content